高 FAS 表达与乳腺癌中紫杉烷和靶向药物的更好预后和疗效相关。

High FAS expression correlates with a better prognosis and efficacy of taxanes and target regents in breast cancer.

机构信息

Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang, China.

出版信息

Cancer Biomark. 2021;32(2):207-219. doi: 10.3233/CBM-203125.

DOI:10.3233/CBM-203125

PMID:34092611

Abstract

BACKGROUND

FAS can serve as both an oncogene and a suppresser in different malignancies, and the prognostic value of FAS remains controversial.

METHODS

The Oncomine database, KM-Plotter and bc-GenExMiner platform were adopted to analyze the prognostic value of FAS in breast cancer. Breast cancer tissue microarrays were further used to verify these data. The Cell Miner Tool was used to predict the value of FAS mRNA expression in predicting the efficacies of clinical drugs.

RESULTS

We found that both FAS mRNA and protein expression level significantly reduced in breast carcinoma. In addition, high FAS expression indicates a better metastatic relapse-free survival. Interestingly, FAS was associated with a better prognosis in different subtypes of breast cancer patients, namely, only in grade II and III, lymph nodal positive or p53 wild-type patients. The data from the Cell Miner Tool revealed that FAS mRNA expression was correlated with the efficacy of the first-line chemotherapeutic taxane agents and target drugs including olaparib and everolimus.

CONCLUSIONS

FAS expression correlates with a better prognosis in breast cancer and may provide an effective clinical strategy to predict the sensitivity of taxanes and targeted drugs.

摘要

背景

FAS 可在不同的恶性肿瘤中作为癌基因和抑癌基因，其预后价值仍存在争议。

方法

采用 Oncomine 数据库、KM-Plotter 和 bc-GenExMiner 平台分析 FAS 在乳腺癌中的预后价值。进一步使用乳腺癌组织微阵列验证这些数据。使用 Cell Miner 工具预测 FAS mRNA 表达水平对临床药物疗效的预测价值。

结果

我们发现 FAS mRNA 和蛋白表达水平在乳腺癌中均显著降低。此外，高 FAS 表达预示着更好的转移复发无进展生存期。有趣的是，FAS 与不同亚型乳腺癌患者的预后相关，即仅在 II 级和 III 级、淋巴结阳性或 p53 野生型患者中相关。Cell Miner 工具的数据显示，FAS mRNA 表达与一线化疗紫杉烷类药物和靶向药物（包括奥拉帕利和依维莫司）的疗效相关。